Home › Funds › Ikarian Capital, LLC › PHVS
Ikarian Capital, LLC position in PHVS
PHARVARIS N V · Health Care
Ikarian Capital, LLC reported holding 308,856 shares of PHVS (PHARVARIS N V) in its Q2 2026 13F filing — a position valued at US$10.7M, representing 1.72% of its reported portfolio and ranking #17 among its reported holdings. Ikarian Capital, LLC has disclosed PHVS holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Ikarian Capital, LLC's PHVS position evolved
Ikarian Capital, LLC first disclosed a stake in PHVS in Q3 2025 at 210,165 shares (US$5.2M). The position peaked in Q1 2026 at 486,856 shares, worth US$13.8M. Across 4 filings, Ikarian Capital, LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 308,856 shares valued at US$10.7M — a reduction of -178,000 shares quarter over quarter.. Notable position changes include a 132% increase in Q4 2025 (shares rose 2% over the following quarter), a 37% trim in Q2 2026 (shares fell 8% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 210.16K | $5.24M | New |
| Q4 2025 | 486.86K | $13.51M | Add |
| Q1 2026 | 486.86K | $13.75M | Hold |
| Q2 2026 | 308.86K | $10.68M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PHVS and 13F data
PHVS (PHARVARIS N V) is a Health Care company. 49 other funds we track also report a position in PHVS — the largest reported positions include GENERAL ATLANTIC, L.P. (US$226.5M), Foresite Capital Management IV, LLC (US$165.2M), venBio Partners LLC (US$160.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PHVS
- GENERAL ATLANTIC, L.P. 6.55M sh · $226.53M · Q2 2026
- Foresite Capital Management IV, LLC 4.78M sh · $165.24M · Q2 2026
- venBio Partners LLC 4.64M sh · $160.57M · Q2 2026
- EQT Fund Management S.a r.l. 3.42M sh · $118.42M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 3.38M sh · $116.74M · Q2 2026
- Bain Capital Life Sciences Investors, LLC 2.68M sh · $92.52M · Q2 2026
- Commodore Capital LP 1.43M sh · $49.28M · Q2 2026
- Novo Holdings A/S 1.40M sh · $48.41M · Q2 2026
- Saturn V Capital Management LP 1.31M sh · $45.44M · Q2 2026
- TCG Crossover Management, LLC 1.01M sh · $34.86M · Q2 2026
- Sofinnova Investments, Inc. 881.30K sh · $30.48M · Q2 2026
- 5AM Venture Management, LLC 797.60K sh · $27.58M · Q2 2026
More on Ikarian Capital, LLC
FAQ
How long has Ikarian Capital, LLC held PHVS?
Ikarian Capital, LLC has disclosed PHVS holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
What is Ikarian Capital, LLC's current position in PHVS?
As of Q2 2026, Ikarian Capital, LLC holds 308.86K shares of PHVS (PHARVARIS N V), valued at $10.68M, representing 1.72% of its reported portfolio and ranking #17.
Has Ikarian Capital, LLC been buying or selling PHVS?
In the latest 13F filing (Q2 2026), Ikarian Capital, LLC reduced its position in PHVS. The position peaked in Q1 2026 at 486.86K shares.
Which other funds hold PHVS?
Other major institutional holders of PHVS include GENERAL ATLANTIC, L.P., Foresite Capital Management IV, LLC, venBio Partners LLC, among 49 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.